Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toludesvenlafaxine sustained-release tablets for treatment-resistant depression
ChiCTR2400080665Phase 4Not yet recruiting
- Sponsor
- Shandong Mental Health Center
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toludesvenlafaxine in treatment-resistant depression (TRD), sponsored by Shandong Mental Health Center. Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale score from baseline at week 8. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
toludesvenlafaxine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on ChiCTR2400080665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080665.